NCT05634746: An ongoing trial by Ellodi Pharmaceuticals, LP
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05634746 |
|---|---|
| Title | Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, Followed by a Single-arm Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 29, 2022 |
| Completion date | Aug. 12, 2024 |
| Required reporting date | Aug. 12, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |